SOURCES SOUGHT
Q -- Phenotypic Screening of Candidate Drugs to Treat Alzheimer�s Disease
- Notice Date
- 7/24/2020 11:09:05 AM
- Notice Type
- Sources Sought
- NAICS
- 621511
— Medical Laboratories
- Contracting Office
- NATIONAL INSTITUTES OF HEALTH NIDA Bethesda MD 20892 USA
- ZIP Code
- 20892
- Solicitation Number
- HHS-NIH-NIDA-75N95020Q00216
- Response Due
- 8/10/2020 11:00:00 AM
- Archive Date
- 08/25/2020
- Point of Contact
- Diedra Prophet, Phone: 3014028070, Karen Mahon
- E-Mail Address
-
diedra.prophet@nih.gov, karen.mahon@nih.gov
(diedra.prophet@nih.gov, karen.mahon@nih.gov)
- Description
- Description:� This is a Sources Sought notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding the availability and capability of all qualified sources to perform a potential requirement. This notice is issued to help determine the availability of qualified companies technically capable of meeting the Government requirement and to determine the method of acquisition.� It is not to be construed as a commitment by the Government to issue a solicitation or ultimately award a contract.� Responses will not be considered as proposals or quotes.� No award will be made as a result of this notice.� The Government will NOT be responsible for any costs incurred by the respondents to this notice.� This notice is strictly for research and information purposes only. Background: Research in the NIA IRP has identified several FDA approved drugs that may target metabolic abnormalities associated with AD and be of utility as effective disease-modifying treatments. Repurposing of approved drugs for AD is a promising approach that can accelerate the development of novel AD treatments. As art of the DREAM study, pharmacoepidemiologic analyses of approximately 20 FDA approved drugs will be performed to test whether older individuals exposed to these �candidate AD treatments� are at owner risk of AD. In parallel with these analyses, testing will also determine whether these drugs also ameliorate pathological changes associated with AD at the cellular level. Purpose and Objectives: The purpose of this acquisition is to identify effective treatments for Alzheimer�s disease (AD). With the repeated failures of multiple pivotal phase-III clinical trials in patients with AD, it is critical to test novel methods of discovering disease-modifying AD treatments. As part of an ongoing study called the Drug Repurposing for Effective Alzheimer�s Medicines (DREAM) study, the NIA IRP is testing whether exposure to commonly prescribed, FDA-approved drugs will be associated with protection against AD. DREAM will test approximately 20 drugs that have been nominated as �candidate AD treatments.� Project requirements: The Contractor shall furnish all the necessary services, qualified personnel, material, equipment, and facilities as needed to perform the�requirements below: Perform cell culture based phenotypic screening of 20 FDA approved drugs to test their potential utility as treatments for Alzheimer�s disease (AD) Perform statistical analysis to derive dose-response profiles for each drug in the phenotypic screening assays. The phenotypic screening shall be performed to test the following read-outs: � ?-amyloid1-42 (A?) toxicity �A? clearance A? seretion Tau aggregation Tau phosphorylation Neuroinflamamtion Neurite outgrowth Anticipated period of performance: September 30, 2020 � September 29, 2021 Capability statement /information sought. Respondents must provide, as part of their responses, a capability statement that clearly identifies information regarding respondents�: (a) staff expertise, including their availability, experience, and formal and other training; (b) current in-house capability and capacity to perform the work; (c) prior completed projects of similar nature; (d) corporate experience and management capability; and (e) examples of prior completed Government contracts, references, and other related information; The respondent must also provide their DUNS number, organization name, address, point of contact, and size and type of business (e.g., 8(a), HubZone, etc., pursuant to the applicable NAICS code and any other information that may be helpful in developing or finalizing the acquisition requirements. One (1) copy of the response is required and must be in Microsoft Word or Adobe PDF format using 11-point or 12-point font, 8-1/2� x 11� paper size, with 1� top, bottom, left and right margins, and with single or double spacing. The information submitted must be in an outline format that addresses each of the elements of the project requirement and in the capability statement /information sought paragraphs stated herein.� A cover page and an executive summary may be included but is not required. The response is limited to ten (10) page limit.� The 10-page limit does not include the cover page, executive summary, or references, if requested. The response must include the respondents� technical and administrative points of contact, including names, titles, addresses, telephone and fax numbers, and e-mail addresses. All responses to this notice must be submitted electronically to the Contract Specialist and Contracting Officer.� Facsimile responses are NOT accepted. The response must be submitted to Diedra Prophet at e-mail address Diedra.Prophet@nih.gov and Karen Mahon at e-mail address Karen.Mahon@nih.gov. The response must be received on or before August 10, 2020 at 2:00 pm Eastern Time. Disclaimer and Important Notes:� This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization�s qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a presolicitation synopsis and solicitation may be published in Federal Business Opportunities. However, responses to this notice will not be considered adequate responses to a solicitation. Confidentiality: No proprietary, classified, confidential, or sensitive information should be included in your response. the Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s).
- Web Link
-
SAM.gov Permalink
(https://beta.sam.gov/opp/428ad4a7325b4224acc23e3032c0c1e1/view)
- Place of Performance
- Address: AUT
- Country: AUT
- Country: AUT
- Record
- SN05733602-F 20200726/200724230149 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |